BRD4 and neoplasm: Both JQ1 and ARV-771 belong to BRD4 inhibitors, which may enhance chemotherapy sensitivity and anti-tumor immunity of chemoradiotherapy by reducing treatment-induced PD-L1 expression in NSCLC (Table 2) (Figure 3) [156].